3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Cyclophosphamide
166
Rituximab
153
Specimen Handling
111
Biopsy
89
Magnetic Resonance Spectroscopy
87
Vincristine
85
Doxorubicin
79
Prednisone
78
fludarabine
68
venetoclax
65
obinutuzumab
60
ibrutinib
54
Lenalidomide
53
Dexamethasone
53
Cytarabine
47
Methotrexate
44
acalabrutinib
42
Etoposide
41
CT-P10
39
blinatumomab
38
Bendamustine Hydrochloride
34
fludarabine phosphate
33
prednylidene
32
Gemcitabine
32
deltacortene
31
Calcium Dobesilate
30
zanubrutinib
29
pembrolizumab
29
glofitamab
27
Nivolumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Alemtuzumab
×
Lymphoid
×
90 days
×
Clear all
NCT03821610
2026-05-05
ALL-RIC
University of Birmingham
Phase 2
Active not recruiting
242 enrolled